OncoMatch

OncoMatch/Clinical Trials/NCT06479239

Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer

Is NCT06479239 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies EGFR FPBMC for pancreas cancer.

Phase 1/2RecruitingUniversity of VirginiaNCT06479239Data as of May 2026

Treatment: EGFR FPBMCThe purpose of this study is to understand the safety and estimate the efficacy of combining anti-cluster of differentiation 3 (CD3) x anti-Epidermal Growth Factor Receptor (EGFR) bispecific antibody fresh peripheral blood mononuclear cells (EGFR FPBMC) for patients with metastatic or unresectable pancreas cancer. Participants receive 8 twice weekly doses and then 8 more doses every 2 weeks of EGFR FPBMC by intravenous infusion.

Check if I qualify

Extracted eligibility criteria

Cancer type

Pancreatic Cancer

Disease stage

Required: Stage III, IV

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Min 1 prior line

Must have received: chemotherapy (gemcitabine, 5FU, capecitabine, albumin-bound paclitaxel)

Therapy should consist of either a gemcitabine, 5FU-based (including capecitabine) or albumin-bound paclitaxel-based regimen

Cannot have received: investigational agent

Treatment with investigational agent within 3 weeks prior to registration

Lab requirements

Blood counts

absolute neutrophil count >= 500/mm3; absolute lymphocyte count >= 400/mm3; platelets >= 75,000/mm3; hemoglobin >= 8 g/dl

Kidney function

serum creatinine < 2.0mg/dl or calculated/measured creatinine clearance >= 50 ml/min

Liver function

bilirubin <= 2 mg/dl; ast and alt <= 5.0 x uln

Cardiac function

no uncontrolled angina or severe ventricular arrhythmias; no clinically significant pericardial disease; no history of myocardial infarction (mi) in the last year before registration; no class 3 or higher new york heart association congestive heart failure

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • University of Virginia · Charlottesville, Virginia

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify